Organic Active Ingredients TRIZ Cases

Phenylene diamine derivatives strengthen tight junction signaling and host-defense peptides to block pathogen translocation without dysbiosis.

Controlled backbone stereochemistry and sugar modifications improve ds oligonucleotide stability, Ago2 activity, and cellular delivery.

Cell-specific neuronal promoters and retrograde AAV targeting improve D1-MSN precision in Parkinson's circuits to restore motor function.

8-azaquinazoline compounds improve SOS1-KRAS inhibition while reducing efflux and enabling brain penetration for metastatic tumor treatment.

Adjusted capivasertib and venetoclax dosing cycles maintain anti-cancer efficacy in B-cell malignancies while reducing body weight loss.

Targeted deuterium substitution at the 3-position slows racemization, preserving stereoisomeric purity and therapeutic activity.

6,6-heterocyclic scaffolds tune DYRK and CLK inhibition to broaden disease coverage while managing selectivity and off-target effects.

Bicyclic C3 glutarimide degrons improve cereblon binding and enable more selective degradation of disease-associated proteins.

Crosslinked polymer DHA analog formulations sustain retinal and inner ear drug levels, overcoming barrier limits without repeated injections.

Allele-specific antisense oligonucleotides selectively silence pathogenic FUS variants while preserving normal FUS expression in ALS and FTD treatment.

Stimulus-responsive binary copolymer hydrogels occlude tear ducts with better fit, lower extrusion and migration, and easier removal.

A heterocyclic compound and neurospheroid model address the lack of reliable evaluation for reducing α-synuclein aggregates in the brain.

LSD1 inhibition during CAR T or NK cell preparation increases naive cells, reduces exhaustion, and improves anti-tumor response.

UV-driven cascade synthesis converts aromatic precursors into complex anticancer polyheterocycles with higher selectivity under mild conditions.

Early PDE5 inhibitor dosing after low-level blasts helps preserve brain vascular integrity, mitochondrial function, and long-term neurological health.

A substituted gamma-carboline compound targets 5-HT2A and SERT pathways to treat CNS disorders while reducing dopamine-related side effects.

PPI-TAC chroman compounds degrade ERα to improve bioavailability, reduce resistance, and strengthen treatment of ER-mediated breast cancer.

PROTAC compounds target residual immunoglobulin light chains for degradation or stabilization to reduce organ toxicity in light chain amyloidosis.

Cationic amphiphilic compounds replace ionizable lipids in LNPs to improve nucleic acid endosomal escape while reducing toxicity.

Blocking S100A9-ALDH1A1-retinoic acid signaling with pan-RAR antagonists helps curb osimertinib-refractory brain relapse in EGFR-mutant lung cancer.

Selective glycolipid activators boost iNKT cytokine release through CD1d engagement to reduce senescent cells linked to chronic disease.

High-concentration non-cross-linked hyaluronan relieves dry eye, skin, and wound pain by combining elasticity with TRPV1 interaction.

Anti-PD-L1 antibodies enhance T-cell function and cell-mediated immunity while addressing exhaustion in tumors and chronic infections.

A selective NOX2 inhibitor compound expands treatment options by blocking ROS-driven pathways in inflammatory, fibrotic, and neurodegenerative disease.

MC16 promotes mitochondrial biogenesis in injured renal tissue, improving kidney function and lowering injury markers in AKI.

Particle size control and granulation turn AN0025 into tablets with more uniform dissolution and lower in vivo exposure variability.

Targeting SCD1 enzyme activity reduces liver lipid accumulation and improves liver function in NAFLD and NASH without relying on transplant.

Tramadol enables a preservative-free ophthalmic composition that inhibits microbial growth while avoiding corneal epithelial disorders.

Controlled low-temperature crystallization creates a stable TETA tetrahydrochloride form that resists humidity and supports oral Wilson's disease treatment.

A 6,6-heterocyclic scaffold targets DYRK and CLK kinases to modulate WNT signaling across neurodegenerative, autoimmune, and cancer therapy.

Xanthine compounds are tuned to inhibit or activate TRPC4/5 channels with higher selectivity and efficacy for TRPC-related diseases.

A cationic lipid composition balances transfection efficiency and toxicity by enabling extrahepatic, spleen-directed nucleic acid delivery.

Pyrazolopyridine derivatives inhibit USP1 to expand treatment options for DNA repair and tumor diseases linked to USP1 activity.

A ruthenium-based visible light system cross-links PEG hydrogels without UV lamps, reducing cell toxicity while preserving gel formation control.

Targeted budesonide release in the distal ileum treats IgA nephropathy while lowering pathogenic IgA and limiting systemic side effects.

Steady transdermal dronabinol delivery avoids oral variability and first-pass metabolism while improving dosing convenience and serum consistency.

Pyrazolopyrimidine SRC kinase inhibitors improve selectivity over ABL to reduce cardiotoxicity, immunosuppression, and pro-oncogenic effects.

Combining CD4 lymphocyte depletion with checkpoint inhibitors reduces Treg suppression and strengthens immune stimulation for cancer and infectious disease treatment.

C3-disubstituted 19-nor steroids improve solubility and metabolic stability, enabling safer oral treatment of CNS disorders.

Small molecules bind ATXN3 pre-mRNA to shift splicing, lower full-length ATXN3, and help delay Spinocerebellar Ataxia 3 progression.

A heparin-loaded depot and foam filter reduce inflammation, coagulation, and cannula encapsulation to extend insulin infusion at one site.

Combining chidamide and celecoxib modulates the tumor microenvironment to improve immune response, overcome resistance, and boost anti-cancer activity.

Biodegradable tail groups in ionizable cationic lipids improve nucleic acid delivery while reducing toxicity and metabolic clearance.

Localized 6,7-epoxytiglienone treatment triggers immune-mediated regression of distant tumours, addressing the rarity of systemic abscopal effects.

Novel urea compounds inhibit NAMPT through modular structural variation, addressing inadequate cancer treatment with a targeted therapeutic approach.

A benidipine tablet uses polyvinyl alcohol and low disintegrant loading to improve dissolution, stability, and content uniformity.

Antioxidant additives keep dexamethasone cyclodextrin eye drops pH-stable during storage, limiting oxidation and degradation.

Rho kinase inhibition with fasudil reduces cortical dementia wandering, helps prevent elopement, and avoids chemical restraints.

Selective receptor targeting with roluperidone helps prevent schizophrenia relapse while avoiding dopamine-related sedation and Parkinsonism.

Cell-penetrating antibodies non-covalently bind nucleic acids to improve cellular uptake while avoiding viral vector complexity and immunological risks.